0001209191-22-016526.txt : 20220304 0001209191-22-016526.hdr.sgml : 20220304 20220304205802 ACCESSION NUMBER: 0001209191-22-016526 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sepp-Lorenzino Laura CENTRAL INDEX KEY: 0001777421 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 22716014 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS, INC. STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2022-03-01 2022-03-03 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001777421 Sepp-Lorenzino Laura C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Scientific Officer Stock Option (right to buy) 79.85 2022-03-01 4 A 0 20203 0.00 A 2032-02-28 Common Stock 20203 20203 D The original Form 4 incorrectly reported the number of options granted as 13,816. This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. /s/ James Basta, attorney-in-fact 2022-03-04